ReviewExpert review of vaccines2010
Antibody-profiling technologies for studying humoral responses to infectious agents.
Review in Expert review of vaccines, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 76 citations in OpenAlex.
- Serological differentiation between COVID-19 and SARS infections.Emerging microbes & infections · 2020Trial
- Ultrarapid Measurement of Diagnostic Antibodies by Magnetic Capture of Immune Complexes.Scientific reports · 2017Trial
- Development of a multi-species luciferase-based double-antigen ELISA for the detection of antibodies against influenza A virus H5 clade 2.3.4.4b.Journal of clinical microbiology · 2026Article
- Serum antibody screening using glycan arrays.Chemical Society reviews · 2024Review
- Article
- Assays for Detecting Henipavirus Antibodies.Methods in molecular biology (Clifton, N.J.) · 2023Article
- A new luciferase immunoprecipitation system assay provided serological evidence for missed diagnosis of severe fever with thrombocytopenia syndrome.Virologica Sinica · 2022Article
- Article
- Testing Antigens, Antibodies, and Immune Cells in COVID-19 as a Public Health Topic-Experience and Outlines.International journal of environmental research and public health · 2021Review
- Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy.Biomedicines · 2021Article
- Serological Proteome Analysis for the Characterization of Secreted Fungal Protein Antigens.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Evaluation of Antibody Response Directed against Porcine Reproductive and Respiratory Syndrome Virus Structural Proteins.Vaccines · 2020Article
- Plasmodium falciparum immunodominant IgG epitopes in subclinical malaria.Scientific reports · 2020Article
- RNA Viruses ofViruses · 2020Article
- Serological and molecular rapid diagnostic tests for Toxoplasma infection in humans and animals.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Review
- Monitoring Silent Spillovers Before Emergence: A Pilot Study at the Tick/Human Interface in Thailand.Frontiers in microbiology · 2019Article
- Redefining environmental exposure for disease etiology.NPJ systems biology and applications · 2018Article
- Quantitative humoral profiling of the HIV-1 proteome in elite controllers and patients with very long-term efficient antiretroviral therapy.Scientific reports · 2017Article
- Antibody Engineering for Pursuing a Healthier Future.Frontiers in microbiology · 2017Review
- Progress and challenges associated with the development of ricin toxin subunit vaccines.Expert review of vaccines · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Analyses of humoral responses against different infectious agents are critical for infectious disease diagnostics, understanding pathogenic mechanisms, and the development and monitoring of vaccines. While ELISAs are often used to measure antibody responses to one or several targets, new antibody-profiling technologies, such as protein microarrays, can now evaluate antibody responses to hundreds, or even thousands, of recombinant antigens at one time. These large-scale studies have uncovered new antigenic targets, provided new insights into vaccine research and yielded an overview of immunoreactivity against almost the entire proteome of certain pathogens. However, solid-phase antigen arrays also have drawbacks that limit the type of information obtained, including suboptimal detection of conformational epitopes, high backgrounds due to impure antigens and a narrow dynamic range of detection. We have developed a solution-phase antibody-profiling technology, luciferase immunoprecipitation systems (LIPS), which harnesses light-emitting recombinant antigen fusion proteins to quantitatively measure patient antibody titers. Owing to the highly linear light output of the luciferase reporter, some antibodies can be detected without serum dilution in a dynamic range of detection often spanning seven orders of magnitude. When LIPS is applied iteratively with multiple target antigens, a high-definition antibody profile is obtained. Here, we discuss the application of these different antibody-profiling technologies and their associated limitations with particular emphasis on protein microarrays. We also describe LIPS in detail and discuss several clinically relevant uses of the technology. Together, these new technologies offer new tools for understanding humoral responses to known and emerging infectious agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.